Skip to main content

Table 1 Baseline characteristics and design variables of the included studies

From: Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis

Reference Number (M/F) C/R/RS ST CRT before and after ST Age mean ± SD/ median (range) Methods Rate(+) Follow up mean ± SD/median (range) Tumor stage HR (method no.) OM Surgery
Barbazan 2014 [30] 50(37/13) 34/14 baseline NO/YES 64.5 ± 10.3; 31-84 RT-PCR 13/50 0-40 mCRC PFS,OS(3) PFS,OS, NR
    4 W; 16 W YES/YES 64.5 ± 10.3; 31-84 RT-PCR 12/50; 15/50 0-40 mCRC PFS,OS(3); PFS,OS(11) PFS,OS, RECIST NR
Kuboki 2013 [34] 63(34/29) 41/22/0 baseline NO/YES 61(33–81) Cellsearch 19/63 median:8.7 mCRC PFS,OS(3) PFS,OS, RECIST NR
Lu 2013 [36] 90(51/39) 90/0/0 1,4 W YES/YES 63.1 ± 12.9 membrane-array 21/90 36(18–61) III stage PFS,OS(3) PFS,OS YES
Iinuma(1) 2013 [35] Training: 420(224/196) NR baseline NO/YES 66.0 ± 12.4 RT-PCR 57/150 36.9 ± 19.5 Dukes’ C PFS,OS(3) PFS,OS YES
Iinuma(2) 2013 [35] Validation: 315(175/140) NR baseline NO/YES 67.5 ± 11.8 RT-PCR 35/97 37.1 ± 18.1 Dukes’ C PFS,OS(3) PFS,OS YES
Sastre 2012 [26] 180(118/62) 121/40/19 baseline NO/YES 65(40–82) Cellsearch 85/180 29(0–53.2) mCRC PFS,OS(3) PFS,OS, RECIST 123YES
  147 NR cycle3 YES/YES NR Cellsearch 23/147 NR mCRC PFS,OS(3) PFS,OS, RECIST 123YES
de Albuquerque 2012 [27] 60(43/17) NR baseline NO/YES 65.2(40–80) RT-PCR 23/33 8.1(6.4-9.7) II-IV stage PFS(10) PFS, RECIST NR
  33 NR 1-4 W; 5-8 W; 9-12 W YES/YES NR RT-PCR 18/33; 19/33; 17/33 NR NR NR RECIST NR
Matsusaka 2011 [28] 64(31/33) 36/28 baseline NO/YES 59(18–72) Cellsearch 12/64 0-36 mCRC PFS(3);OS(10) PFS,OS, RECIST NR
  / NR 2 W; 8-12 W YES/YES NR Cellsearch 7/63; 4/60 NR mCRC PFS(3);OS(10) PFS,OS, RECIST NR
Konigsberg 2010 [33] 38(23/15) NR mixed NO/YES 65(44–82) ICC 23/38 11.7(8.4-14.9) mCRC PFS,OS(3) PFS,OS, RECIST NR
Yalcin 2010 [32] 93(50/43) NR mixed part NO/YES 56(24–78) Cellsearch 30/93 6 II-IV stage NR RECIST PART YES
Tol 2010 [29] 467(284/183) 225/122/120 baseline NO/YES 63(27–83) Cellsearch 129/451 16.8 mCRC PFS,OS(3) PFS,OS, RECIST NO
  / NR 1-2 W YES/YES NR Cellsearch 21/368 NR mCRC PFS,OS(3) PFS,OS, RECIST NR
  / NR 3-5 W; 6-12 W; 13-20 W YES/YES NR Cellsearch 17/320; 18/336; 16/254 NR mCRC PFS,OS(3) PFS,OS, RECIST NR
Yen 2009 [37] 76(44/32) 55/21 NR NR 64(39–83) membrane-array 30/76 20(4–34) mCRC PFS,OS(3) PFS,OS, RECIST YES
Cohen 2008 [11] 430(238/192) 292/71/66 baseline NO/YES 64(22–92) Cellsearch 107/413 12.6 ± 6.5/11.0(0.8-30.0) mCRC PFS,OS(11) PFS,OS, RECIST NR
  / NR 3-5 W YES/YES NR Cellsearch 38/320 NR mCRC PFS,OS(11) PFS,OS, RECIST NR
  / NR 1-2 W; 6-12 W; 13-20 W YES/YES NR Cellsearch 41/357; 25/310; 21/193 NR mCRC PFS,OS(11) PFS,OS, RECIST NR
Staritz 2004 [31] 42 NR baseline NO/YES NR RT-PCR 19/41 13.7(1.9-25.4) mCRC OS(10) OS NR
    1 day YES/YES NR RT-PCR 23/40 13.7(1.9-25.4) mCRC OS(10) OS NR
  1. NOTE, M/F: Male/female; C/R/RS: Colon/rectum/rectosigmoid; ST: Sample time; CRT: Chemoradiotherapy before and after sampling time; SD: Standard deviation; Rate (+): Rate of CTCs positive patients, n/N (%); OM: Outcome measured; Mixed: samples without separation based on sampling time; mCRC: metastatic colorectal cancer; OS: Overall survival; PFS: Progression-free survival; HR: Hazard Ratio; RECIST: Response evaluation criteria in solid tumors; ICC: Immunocytochemistry; RT-PCR: Reverse-transcriptase polymerase chain reaction; NR: Not reported.